Today, the first monoclonal antibodies, lecanemab and donanemab ... could have beneficial effects on cognition through ...

BioArctic AB (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) has presented the design of its proprietary BrainTransporter (BT) platform at the ...

Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

The data may help explain lecanemab’s therapeutic success, the authors suggested. They noted that for donanemab, additional studies of plaque binding will be needed to elucidate its mechanism of ...

Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...

in the successful trials for Eli Lilly's donanemab and Eisai's lecanemab. The many doctors I met decided to participate in ...

Their precise interaction remains elusive; however, last year disclosed shining hope when a drug, lecanemab, was revealed to ...

The drug has the same target — amyloid beta — as the approved Alzheimer's therapies Leqembi (lecanemab), developed ... two other drugs with the same mechanism of action (“MoA”) on the ...